ATAD3B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This product provides a diverse pool of cells with targeted disruption of the ATAD3B gene, enabling loss-of-function studies in a cancer-relevant background. The polyclonal format avoids clonal selection artifacts and preserves population-level heterogeneity.
The A-549 cell line is a prominent model of human lung adenocarcinoma, exhibiting adherent epithelial morphology and characteristic KRAS-mutant signaling. Extensively utilized in cancer biology and respiratory research, these cells provide a well-defined platform for investigating tumorigenic mechanisms and evaluating therapeutic responses.
ATAD3B encodes a mitochondrial inner membrane ATPase that integrates cholesterol trafficking, mtDNA organization, and mitochondrial dynamics with cell survival pathways. It is transcriptionally controlled by c-Myc, NRF1, HIF1??, p53, and ER stress, coupling oncogenic and metabolic signals. Within the mitochondria, ATAD3B interacts with ATAD3A, TFAM, prohibitin, and the MICOS complex to stabilize cristae and nucleoids. Downstream, ATAD3B suppresses mitophagy and apoptosis by regulating PINK1, Parkin, Bcl-2 family proteins, and OPA1, thereby sustaining oxidative phosphorylation. Consequently, ATAD3B promotes cancer cell survival and stemness, especially in lung adenocarcinoma.
In A-549 cells, ATAD3B knockout impairs mitochondrial inner membrane organization, leading to mtDNA depletion and disrupted cholesterol traffic. This triggers PINK1/Parkin-dependent mitophagy and pro-apoptotic Bcl-2 activation, reducing ATP production and increasing sensitivity to mitochondrial stress. Loss of ATAD3B attenuates mTOR signaling and diminishes stem-like properties, highlighting its role in tumor maintenance. The polyclonal knockout model captures the heterogeneous impact of ATAD3B loss, offering a physiologically relevant system for studying mitochondrial dysfunction in lung adenocarcinoma.
This knockout model enables investigation of mitochondrial function in lung cancer, including ATAD3B-dependent apoptosis, mitophagy, and drug sensitivity. Researchers can perform RT-qPCR and Western blotting for target validation, Seahorse assays for metabolic profiling, mtDNA copy number qPCR, and immunofluorescence for mitochondrial markers. Functional assays such as Annexin V flow cytometry, mt-Keima mitophagy monitoring, colony formation, and migration assays provide multiparametric readouts. For additional product information or technical support, please contact Ascent Research.
